Analyst Naz Rahman of Maxim Group reiterated a Buy rating on Vivani Medical, retaining the price target of $4.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Naz Rahman has given his Buy rating due to a combination of factors that highlight Vivani Medical’s promising prospects. The company is advancing its NPM-139 semaglutide implant, which offers a unique six-month administration cycle, potentially addressing patient compliance issues associated with more frequent dosing schedules. This innovation could capture a significant market opportunity, given the well-established efficacy and safety profile of semaglutide, known from products like Ozempic and Wegovy.
Additionally, the recent acquisition of Metsera by Pfizer underscores the high value placed on differentiated, long-duration obesity treatments. This transaction, involving a substantial bidding war, suggests strong interest from major pharmaceutical companies in such assets, which bodes well for Vivani’s strategy. With sufficient financial resources to support its operations and clinical trials, Vivani is well-positioned to capitalize on its innovative approach, reinforcing Naz Rahman’s confidence in a Buy recommendation.
VANI’s price has also changed moderately for the past six months – from $1.050 to $1.355, which is a 29.05% increase.